Involvement of TWEAK in interferon γ-stimulated monocyte cytotoxicity

被引:153
作者
Nakayama, M
Kayagaki, N
Yamaguchi, N
Okumura, K
Yagita, H
机构
[1] Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan
[2] Juntendo Univ, Sch Med, Allergy Res Ctr, Bunkyo Ku, Tokyo 1138421, Japan
[3] Japan Sci & Technol Corp, CREST, Tokyo 1010062, Japan
关键词
TWEAK; TRAIL; IFN-gamma; monocyte; cytotoxicity;
D O I
10.1084/jem.192.9.1373
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
TWEAK, a new member of the tumor necrosis factor (TNF) family, induces cell death in some tumor cell Lines, but its physiological functions are largely unknown. In this study, we investigated the expression and function of TWEAK in human peripheral blood mononuclear cells (PBMCs) by using newly generated anti-human TWEAK mAbs. Although freshly isolated PBMCs expressed no detectable level of TWEAK on their surfaces, a remarkable TWEAK expression was rapidly observed on monocytes upon stimulation with interferon (IFN)-gamma but not with IFN-alpha or lipopolysaccharide. Cytotoxic activity of IFN-gamma -stimulated monocytes against human squamous carcinoma cell line HSC3 was inhibited partially by anti-TWEAK mAb alone and almost completely by combination with anti-TRAIL (TNF-related apoptosis-inducing ligand) mAb. These results revealed a novel pathway of monocyte cytotoxicity against tumor cells that is mediated by TWEAK and potentiated by IFN-gamma.
引用
收藏
页码:1373 / 1379
页数:7
相关论文
共 26 条
  • [1] Death receptors: Signaling and modulation
    Ashkenazi, A
    Dixit, VM
    [J]. SCIENCE, 1998, 281 (5381) : 1305 - 1308
  • [2] TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis
    Chicheportiche, Y
    Bourdon, PR
    Xu, HD
    Hsu, YM
    Scott, H
    Hession, C
    Garcia, I
    Browning, JL
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (51) : 32401 - 32410
  • [3] Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95
    Chinnaiyan, AM
    ORourke, K
    Yu, GL
    Lyons, RH
    Garg, M
    Duan, DR
    Xing, L
    Gentz, R
    Ni, J
    Dixit, VM
    [J]. SCIENCE, 1996, 274 (5289) : 990 - 992
  • [4] FEINMAN R, 1987, J IMMUNOL, V138, P635
  • [5] PROCESSING OF TUMOR-NECROSIS-FACTOR-ALPHA PRECURSOR BY METALLOPROTEINASES
    GEARING, AJH
    BECKETT, P
    CHRISTODOULOU, M
    CHURCHILL, M
    CLEMENTS, J
    DAVIDSON, AH
    DRUMMOND, AH
    GALLOWAY, WA
    GILBERT, R
    GORDON, JL
    LEBER, TM
    MANGAN, M
    MILLER, K
    NAYEE, P
    OWEN, K
    PATEL, S
    THOMAS, W
    WELLS, G
    WOOD, LM
    WOOLLEY, K
    [J]. NATURE, 1994, 370 (6490) : 555 - 557
  • [6] THE TRANSMEMBRANE FORM OF TUMOR-NECROSIS-FACTOR IS THE PRIME ACTIVATING LIGAND OF THE 80 KDA TUMOR-NECROSIS-FACTOR RECEPTOR
    GRELL, M
    DOUNI, E
    WAJANT, H
    LOHDEN, M
    CLAUSS, M
    MAXEINER, B
    GEORGOPOULOS, S
    LESSLAUER, W
    KOLLIAS, G
    PFIZENMAIER, K
    SCHEURICH, P
    [J]. CELL, 1995, 83 (05) : 793 - 802
  • [7] Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL
    Griffith, TS
    Wiley, SR
    Kubin, MZ
    Sedger, LM
    Maliszewski, CR
    Fanger, NA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (08) : 1343 - 1353
  • [8] TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages
    Kaplan, MJ
    Ray, D
    Mo, RR
    Yung, RL
    Richardson, BC
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 164 (06) : 2897 - 2904
  • [9] METALLOPROTEINASE-MEDIATED RELEASE OF HUMAN FAS LIGAND
    KAYAGAKI, N
    KAWASAKI, A
    EBATA, T
    OHMOTO, H
    IKEDA, S
    INOUE, S
    YOSHINO, K
    OKUMURA, K
    YAGITA, H
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (06) : 1777 - 1783
  • [10] Polymorphism of murine Fas ligand that affects the biological activity
    Kayagaki, N
    Yamaguchi, N
    Nagao, F
    Matsuo, S
    Maeda, H
    Okumura, K
    Yagita, H
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) : 3914 - 3919